Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: Possible lack of relationship to immunosuppressive activity

British Journal of Pharmacology

Volumn 118, Issue 4, 1996, Pages 885-892

  Lo Russo, A ^a   Passaquin, A C ^a   Andre P ^a,b   Skutella, M ^a   Ruegg U T ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

45Ca2+ efflux; Cyclosporin A; Cyclosporins; Fura 2; Hypertensive side effect; Intracellular calcium; Mesenteric arteries; Smooth muscle cells; Vasoconstrictor activity

Indexed keywords

ANGIOTENSIN; ASCOMYCIN; CALCINEURIN; CALCIUM ION; CYCLOPHILIN; CYCLOSPORIN A; CYCLOSPORIN H; ENDOTHELIN 1; NORADRENALIN; SEROTONIN; THAPSIGARGIN; VALSPODAR; VASOPRESSIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HYPERTENSION; IMMUNOMODULATION; MALE; MESENTERIC ARTERY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0029785359     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15482.x     Document Type: Article

References (61)

1. AUCH-SCHWELK, W., BOSSALLER, C., GOTZE, S., THELEN, J. & FLECK, E. (1993). Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A. J. Cardiovasc. Pharmacol., 21, 435-440.
2. AUCH-SCHWELK, W., DUSKE, E., HINK, U., BETZ, M., UNKELBACH, M. & FLECK, E. (1994). Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension, 23, 832-837.
3. BOESCH, D., MULLER, K., POURTIER-MANZANEDO, A & LOOR, F. (1991). Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res., 196, 26-32.
4. BOKEMEYER, D., KRAMER, H.J. & MEYER-LEHNERT, H. (1993). Atrial natriuretic peptide blunts the cellular effects of cyclosporine in smooth muscle. Hypertension, 21, 166-172.
5. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
6. BRILLANTES, A.B., ONDRIAS, K., SCOTT, A., KOBRINSKY, E., ONDRIASOVA, E., MOSCHELLA, M.C., JAYARAMAN, T., LANDERS, M., EHRLICH, B.E. & MARKS, A.R (1994). Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell, 77, 513-523.
7. 2+ flux. Cell, 83, 463-472.
8. CHIU, P.J., VEMULAPALLI, S., SABIN, C., RIVELLI, M., BERNARDINO, V. & SYBERTZ. E.J. (1992). Sympathoadrenal stimulation, not endothelin, plays a role in acute presser response to cyclosporine in anesthetized rats. J. Pharmacol. Exp. Ther., 261, 994-999.
9. COHEN, D.J., LOERTSCHER, R., RUBIN, M.F., TILNEY, N.L., CARPENTER, C.B. & STROM, T.B. (1984). Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann. Intern. Med., 101, 667-682.
10. 2 receptor antagonists on cyclosporin A renal vasoconstriction. Am. J. Physiol., 267, F443-F449.
11. COPELAND, K.R. & YATSCOFF, R.W. (1992). Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation, 53, 640-645.
12. 2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. J. Biol. Chem., 264, 1146-1155.
13. DIEDERICH, D., SKOPEC, J., DIEDERICH, A. & DAI, F.X. (1994). Cyclosporine produces endothelial dysfunction by increased production of Superoxide. Hypertension, 23, 957-961.
14. DUMONT, F.J., KASTNER, C., IACOVONE, F., JR. & FISCHER, P.A. (1994). Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes. J. Pharmacol. Exp. Ther., 268, 32-41.
15. DUMONT, F.J., STARUCH, M.J., KOPRAK, S.L., SIEKIERKA, J.J., LIN, C.S., HARRISON, R., SEWELL, T., KINDT, V.M., BEATTIE, T.R., WYVRATT, M. & SIGAL, N.H. (1992). The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J. Exp. Med., 176, 751-760.
16. FAHR, A. (1993). Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet., 24, 472-495.
17. FLIRI, H., BAUMANN, G., ENZ, A., KALLEN, J., LUYTEN, M., MIKOL, V., MOVVA, R., QUESNIAUX, V., SCREIER, M., WALKINSHAW, M., WENGER, R., ZENKE, G. & ZURINI, M. (1993). Cyclosporins. Structure-activity relationships. Ann. N.Y. Acad. Sci., 696, 47-53.
18. 2+. Circ. Res., 74, 477-484.
19. GARLAND, C.J., PLANE, F., KEMP, B.K. & COCKS, T.M. (1995). Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol. Sci., 16, 23-30.
20. GARR, M.D. & PALLER, M.S. (1990). Cyclosporine augments renal but not systemic vascular reactivity. Am. J. Physiol., 258, F211-F217.
21. GRIEFF, M., LOERTSCHER, R., SHOHAIB, S.A. & STEWART, D..J. (1993). Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation, 56, 880-884.
22. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
23. 2+ uptake of mitogen-stimulated lymphocytes. Agents Actions, 15, 556-561.
24. IWAI, J., KANAYAMA, Y., NEGORO, N., INOUE, T., OKAMURA, M. & TAKEDA, T. (1993). Increased gene expression of angiotensin II type IA receptor in aortic smooth muscle cells of cyclosporin A-induced hypertensive rats. J. Hvperten., 11, (Suppl 5), S122-S123.
25. JULIEN, J., FARGE, D., KREFT-JAIS, C., GUYENE, T.T., PLOUIN, P.F., HOUSSIN, D., CARPENTIER, A. & CORVOL, P. (1993). Cyclosporine-induced stimulation of the renin-angiotensin system after liver and heart transplantation. Transplantation, 56, 885-891.
26. KAHAN, B.D. (1989). Cyclosporine. N. Engl. J. Med., 321, 1725-1738.
27. KAYE, D., THOMPSON, J., JENNINGS, G. & ESLER, M. (1993). Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation, 88, 1101-1109.
28. KNOT, H.J., DE REE, M.M., GÄHWILER, B.H. & RÜEGG, U.T. (1991). Modulation of electrical activity and of intracellular calcium oscillations of smooth muscle cells by calcium antagonists, agonists, and vasopressin. J. Cardiovasc. Pharmacol., 18, (Suppl 10), S7-14.
29. KREMER, S., MARGOLIS, B., HARPER, P. & SKORECKI, K. (1989). Cyclosporine induced alterations in vasopressin signalling in the glomerular mesangial cell. Clin. Invest. Med., 12, 201-206.
30. KUNZ, J. & HALL, M.N. (1993). Cyclosporin A, FK506 and rapamycin: More than just immunosuppression. Trends Biochem. Sci., 18, 334-338.
31. LAMB, F.S. & WEBB, R.C. (1987). Cyclosporine augments reactivity of isolated blood vessels. Life Sci., 40, 2571-2578.
32. LANESE, D.M. & CONGER, J.D. (1993). Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J. Clin. Invest., 91, 2144-2149.
33. LIU, J. (1993). FK506 and ciclosporin: Molecular probes for studying intracellular signal transduction. Trends Pharmacol. Sci., 14, 182-188.
34. LOCHER, R., HUSS, R. & VETTER, W. (1991). Potentiation of vascular smooth muscle cell activity by cyclosporin A. Eur. J. Clin. Pharmacol., 41, 297-301.
35. LYSON, T., ERMEL, L.D., BELSHAW, P.J., ALBERG, D.G., SCHREIBER, S.L. & VICTOR, R.G. (1993). Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ. Res., 73, 596-602.
36. LYSON, T., MCMULLAN, D.M., ERMEL, L.D., MORGAN, B.J. & VICTOR, R.G. (1994). Mechanism of cyclosporine-induced sympathetic activation and acute hypertension in rats. Hypertension, 23, 667-675.
37. MACK, M.M., MOLINSKI, T.F., BUCK, E.D & PESSAH, I.N. (1994). Novel modulators of skeletal muscle FKBP12/calcium channel complex from Ianthella basta. Role of FKBP12 in channel gating. J. Biol. Chem., 269, 23236-23249.
38. MARUMO, T., NAKAKI, T., HISHIKAWA, K., SUZUKI, H., KATO, R. & SARUTA, T. (1995). Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension, 25, 764-768.
39. MASON, J. (1990). Pharmacology of cyclosporine (sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol. Rev., 41, 423-434.
40. MCKEON, F. (1991). When worlds collide: immunosuppressants meet protein phosphatases. Cell, 66, 823-826.
41. MEYER-LEHNERT, H. & SCHRIER, R.W. (1989). Potential mechanism of cyclosporine A-induced vascular smooth muscle contraction. Hypertension, 13, 352-360.
42. MORGAN, B.J., LYSON, T., SCHERRER, U. & VICTOR, R.G. (1991). Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats. Hypertension, 18, 458-466.
43. MOSS, N.G., POWELL, S.L. & FALK, R.J. (1985). Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc. Natl Acad. Sci. U.S.A., 82, 8222-8226.
44. MOUQUET, C., BENALIA, H., CARAYON, A., BITKER, M.O., LUCIANI, J. & VIARS, P. (1994). Is the vasoconstrictive effect of cyclosporine mediated by endothelin in kidney transplantation? Transplant. Proc., 26, 277-278.
45. MÜLLER-SCHWEINITZER, E. (1988). Changes in the venous compliance by bradykinin and angiotensin II and its significance for the vascular effects of cyclosporine-A. Naunyn-Schmiedeberg's Arch. Pharmacol., 338, 699-703.
46. NAMBI, P., PULLEN, M., CONTINO, L.C. & BROOKS, D.P. (1990). Upregulation of renal endothelin receptors in rats with cyclosporine A-induced nephrotoxicity. Eur. J. Pharmacol., 187, 113-116.
47. 2+ fluxes in isolated hepatocytes. J. Biol. Chem., 260, 13613-13618.
48. PFEILSCHIFTER, J. (1988). Cyclosporin A augments vasoconstrictor-induced rise in intracellular free calcium in rat renal mesangial cells. Biochem. Pharmacol., 37, 4205-4210.
49. PFEILSCHIFTER, J. & RÜEGG, U.T. (1987). Cyclosporin A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells. Biochem. J., 248, 883-887.
50. REGO, A., VARGAS, R., SUAREZ, K.R., FOEGH, M.L. & RAMWELL, P. W. (1990). Mechanism of Cyclosporin potentiation of vasocon-striction of the isolated rat mesenteric arterial bed: role of extracellular calcium. J. Pharmacol. Exp. Ther., 254, 799-808.
51. RESSUREICAO, F.A., BALLEJO, G., SALGADO, M.C. & FERRAZ, A.S. (1995). Effect of cyclosporine administration on vascular reactivity of the isolated mesenteric bed. Transplant. Proc., 27, 1806-1808.
52. ROULLET, J.B., XUE, H., MCCARRON, D.A., HOLCOMB, S. & BENNETT, W.M. (1994). Vascular mechanisms of cyclosporin-induced hypertension in the rat. J. Clin. Invest., 93, 2244-2250.
53. SCHERRER, U., VISSING. S.F., MORGAN, B.J., ROLLINS, J.A., TINDALL, R.S., RING, S., HANSON, P., MOHANTY, P.K. & VICTOR, R.G. (1990). Cyclosporin induced sympathetic activation and hypertension after heart transplantation. N. Engl. J. Med., 323, 693-699.
54. SCHREIBER, S.L. & CRABTREE, G.R. (1992). The mechanism of action of Cyclosporin A and FK506. Immunol. Today, 13, 136-142.
55. SIGAL, N.H. & DUMONT, F.J. (1992). Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol., 10, 519-560.
56. SOMLYO, A.P. & SOMLYO, A.V. (1994). Signal transduction and regulation in smooth muscle. Nature, 372, 231-236.
57. SWANSON, S.K., BORN, T., ZYDOWSKY, L.D., CHO, H., CHANG, H.Y., WALSH, C.T. & RUSNAK, F. (1992). Cyclosporin-mediated inhibition of bovine calcineurin by cyclophilins A and B. Proc. Natl Acad. Sci. U.S.A., 89, 3741-3745.
58. TEXTOR, S.C., CANZANELLO, V.J., TALER, S.J., WILSON, D.J., SCHWARTZ, L.L., AUGUSTINE, J.E., RAYMER, J.M., ROMERO, J.C., WIESNER, R.H. & KROM, R.A. (1994). Cyclosporine-induced hypertension after transplantation. Mayo Clinic Proc., 69, 1182-1193.
59. VICTOR, R.G., THOMAS, G.D., MARBAN, E. & OROURKE, B. (1995). Presynaptic modulation of cortical synaptic activity by calcineurin. Proc. Natl Acad. Sci. U.S.A., 14, 6269-6273.
60. WENGER, R.M., PAYNE, T.G. & SCHREIER, M.H. (1986). Cyclosporine: chemistry, structure-activity relationships and mode of action. Prog. Clin. Biochem. Med., 3, 157-191.
61. ZHANG, B.X., ZHAO, H. & MUALLEM, S. (1993). Ca(2 + )-dependent kinase and phosphatase control inositol 1,4,5-trisphosphate-mediated Ca2+ release. Modification by agonist stimulation. J. Biol. Chem., 268, 10997-11001.